Ask AI
ProCE Banner Activity

MDT-BRIDGE: Phase II Trial of Neoadjuvant Durvalumab + CT and Subsequent Surgery + Adjuvant Durvalumab or CRT + Consolidation Durvalumab for Resectable Stage IIB-IIIB NSCLC

Conference Coverage
Slideset

The first interim analysis of the phase II MDT-BRIDGE trial suggests that 2 cycles of neoadjuvant durvalumab plus chemotherapy and reassessment of resectability may increase the number of patients with stage IIB-IIIB NSCLC who can undergo definitive treatment.

Released: October 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly